Research analysts at Needham & Company LLC initiated coverage on shares of Juno Therapeutics (NASDAQ:JUNO) in a research note issued to investors on Friday, Marketbeat.com reports. The brokerage set a “buy” rating and a $65.00 price target on the biopharmaceutical company’s stock. Needham & Company LLC’s price target indicates a potential upside of 35.42% from the company’s current price.
JUNO has been the topic of a number of other reports. SunTrust Banks upgraded Juno Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, November 2nd. Morgan Stanley reiterated an “equal weight” rating and issued a $43.00 target price (up from $27.00) on shares of Juno Therapeutics in a research report on Friday, October 6th. Cowen reiterated a “buy” rating and issued a $49.00 target price on shares of Juno Therapeutics in a research report on Friday, October 27th. Raymond James Financial boosted their target price on Juno Therapeutics from $45.00 to $61.00 and gave the stock an “outperform” rating in a research report on Friday, November 3rd. Finally, Wedbush reiterated an “outperform” rating and issued a $64.00 target price (up from $42.00) on shares of Juno Therapeutics in a research report on Thursday, November 2nd. Three research analysts have rated the stock with a sell rating, eight have given a hold rating and nine have issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $46.70.
Juno Therapeutics (NASDAQ JUNO) traded up $0.29 during trading hours on Friday, hitting $48.00. The company had a trading volume of 2,042,474 shares, compared to its average volume of 1,435,300. The company has a quick ratio of 4.77, a current ratio of 4.77 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $5,480.00, a P/E ratio of -14.16 and a beta of 2.32. Juno Therapeutics has a 12 month low of $18.90 and a 12 month high of $63.45.
Juno Therapeutics (NASDAQ:JUNO) last posted its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.73) EPS for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.07. The company had revenue of $44.80 million for the quarter, compared to the consensus estimate of $18.12 million. Juno Therapeutics had a negative return on equity of 32.54% and a negative net margin of 332.05%. The firm’s revenue for the quarter was up 115.4% on a year-over-year basis. During the same period in the previous year, the business earned ($0.57) earnings per share. equities research analysts predict that Juno Therapeutics will post -4.02 earnings per share for the current year.
In other Juno Therapeutics news, EVP Robert Azelby sold 1,816 shares of the company’s stock in a transaction that occurred on Monday, December 18th. The stock was sold at an average price of $44.96, for a total transaction of $81,647.36. Following the sale, the executive vice president now directly owns 70,832 shares in the company, valued at $3,184,606.72. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Steve Harr sold 8,750 shares of the company’s stock in a transaction that occurred on Thursday, December 21st. The shares were sold at an average price of $44.76, for a total value of $391,650.00. Following the sale, the chief financial officer now owns 772,082 shares in the company, valued at $34,558,390.32. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 53,232 shares of company stock worth $2,450,954. Company insiders own 15.08% of the company’s stock.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its stake in shares of Juno Therapeutics by 2.1% during the second quarter. Vanguard Group Inc. now owns 6,285,676 shares of the biopharmaceutical company’s stock valued at $187,879,000 after buying an additional 131,864 shares during the last quarter. Capital International Investors bought a new position in shares of Juno Therapeutics during the third quarter valued at approximately $256,339,000. BlackRock Inc. grew its stake in shares of Juno Therapeutics by 2.6% during the second quarter. BlackRock Inc. now owns 4,294,296 shares of the biopharmaceutical company’s stock valued at $128,357,000 after buying an additional 110,503 shares during the last quarter. State Street Corp grew its stake in shares of Juno Therapeutics by 7.4% during the second quarter. State Street Corp now owns 3,236,384 shares of the biopharmaceutical company’s stock valued at $96,742,000 after buying an additional 222,754 shares during the last quarter. Finally, Capital World Investors grew its stake in shares of Juno Therapeutics by 13.8% during the second quarter. Capital World Investors now owns 2,425,000 shares of the biopharmaceutical company’s stock valued at $72,483,000 after buying an additional 295,000 shares during the last quarter. 69.94% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: “Juno Therapeutics (JUNO) Now Covered by Analysts at Needham & Company LLC” was originally reported by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another site, it was stolen and republished in violation of US & international trademark and copyright law. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/01/05/juno-therapeutics-juno-now-covered-by-analysts-at-needham-company-llc.html.
About Juno Therapeutics
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.